Home › Funds › Nicholas Investment Partners, LP › CYTK

Nicholas Investment Partners, LP position in CYTK

CYTOKINETICS INC COM NEW · Health Care

Nicholas Investment Partners, LP reported holding 209,071 shares of CYTK (CYTOKINETICS INC COM NEW) in its Q2 2026 13F filing — a position valued at US$17.8M, representing 1.12% of its reported portfolio and ranking #22 among its reported holdings. Nicholas Investment Partners, LP has disclosed CYTK holdings in 11 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)209.07K sh
Reported value held$17.81M
Portfolio Weight1.12%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Nicholas Investment Partners, LP's CYTK position evolved

Nicholas Investment Partners, LP first disclosed a stake in CYTK in Q3 2023 at 2,500,000 shares (US$2.1M). The position peaked in Q2 2026 at 209,071 shares, worth US$17.8M. Across 11 filings, Nicholas Investment Partners, LP increased the stake 4 time(s), trimmed it 2 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 209,071 shares valued at US$17.8M — an increase of 139,226 shares quarter over quarter.. Notable position changes include a 100% trim in Q3 2024 (shares fell 11% over the following quarter), a 29314% increase in Q1 2025 (shares fell 18% over the following quarter), a 199% increase in Q2 2026 (shares fell 23% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.50M $2.12M New
Q4 2023 3.00M $5.26M Add
Q1 2024 3.00M $4.76M Hold
Q2 2024 3.00M $3.91M Hold
Q3 2024 11.05K $583.39K Reduce
Q4 2024 11.05K $519.75K Hold
Q1 2025 3.25M $3.72M Add
Q3 2025 62.12K $3.41M New
Q4 2025 70.24K $4.46M Add
Q1 2026 69.84K $4.60M Reduce
Q2 2026 209.07K $17.81M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CYTK and 13F data

CYTK (CYTOKINETICS INC COM NEW) is a Health Care company. 52 other funds we track also report a position in CYTK — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.59B), Avoro Capital Advisors LLC (US$425.9M), RTW INVESTMENTS, LP (US$243.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CYTK

All CYTK fund holders →

FAQ

How long has Nicholas Investment Partners, LP held CYTK?

Nicholas Investment Partners, LP has disclosed CYTK holdings in 11 of the last 12 reported quarters, going back to Q3 2023.

What is Nicholas Investment Partners, LP's current position in CYTK?

As of Q2 2026, Nicholas Investment Partners, LP holds 209.07K shares of CYTK (CYTOKINETICS INC COM NEW), valued at $17.81M, representing 1.12% of its reported portfolio and ranking #22.

Has Nicholas Investment Partners, LP been buying or selling CYTK?

In the latest 13F filing (Q2 2026), Nicholas Investment Partners, LP increased its position in CYTK. The position peaked in Q2 2026 at 209.07K shares.

Which other funds hold CYTK?

Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, RTW INVESTMENTS, LP, among 52 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.